Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > New evidence can help inform decisions on managing early-onset breast cancer linked to BRCA mutations
  • News

New evidence can help inform decisions on managing early-onset breast cancer linked to BRCA mutations

  • 18 December 2024
  • Janet Fricker
In the setting of a hospital office, a smiling woman doctor engages in a communication with patient. The atmosphere exudes understanding, illustrating the dedication of the medical healthcare.
New evidence can help inform decisions on managing early-onset breast cancer linked to BRCA mutations
Total
0
Shares
0
0
0
0
0

Patients with germline BRCA gene mutations and a history of early-onset breast cancer who underwent risk-reducing bilateral mastectomy and/or a risk-reducing salpingo-oophorectomy had lower rates of death than those not undergoing these procedures. The study, presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), held December 10–13, Abstract GS1-08, found that patients who underwent risk-reducing mastectomy had a 35% lower risk of death and that patients who underwent risk-reducing salpingo-oophorectomy had a 42% lower risk of death.

“This global study provides the first evidence that risk-reducing surgeries improve survival outcomes among young BRCA-mutation carriers with a prior history of early-onset breast cancer,” said study presenter Matteo Lambertini, from the University of Genova-IRCCS Policlinico San Martino Hospital, Genoa, Italy. “We believe that our findings are critical for improving the counselling of BRCA-mutation carriers with early-onset breast cancer on cancer-risk management strategies.”

In carriers of harmful BRCA1 and BRCA2 mutations, risk-reducing salpingo-oophorectomy has been shown to improve overall survival, and bilateral risk-reducing mastectomy has been shown to reduce the risk of developing breast cancer, but to have no proven benefit on overall survival. There has, however, been very limited evidence of the benefits of risk-reducing salpingo-oophorectomy and bilateral risk-reducing mastectomy in BRCA carriers with a prior breast cancer diagnosis at a young age.

The retrospective study analysed data from 5,290 patients who, between 2000 and 2020, had been diagnosed with stage I to III invasive breast cancer at 40 years of age or younger. Among the cohort, who were recruited from 109 institutions across five continents, 3,888 underwent at least one risk-reducing procedure, with 2,910 patients receiving bilateral mastectomy, 2,782 salpingo-oophorectomy, and 1,804 both surgeries. The remaining 1,402 patients did not undergo either surgical procedure. The median time from diagnosis to bilateral mastectomy was 0.8 years and to salpingo-oophorectomy was 3 years, with a median follow-up of 5.1 years after bilateral mastectomy and 4.9 years after salpingo-oophorectomy.

Of the patients, 51.5% had node-negative and 45.8% hormone receptor positive breast cancer, with a median age at breast cancer diagnosis of 35 years.

Results for the primary endpoint showed that risk-reducing mastectomy was associated with a significantly reduced risk of death (adjusted hazard ratio [aHR]=0.64, 95%CI 0.53–0.78). The association was observed regardless of the specific BRCA mutation, age at diagnosis, tumour subtype, tumour size, or nodal status.

Risk-reducing salpingo-oophorectomy was also associated with a significantly reduced risk of death (aHR=0.58, 95%CI 0.47–0.70). The association was observed regardless of age at diagnosis, tumour size or nodal status. Notably, higher risk reductions were observed for BRCA1 carriers than BRCA2 carriers (aHR=0.44 for BRCA1 vs 0.85 for BRCA2). Additionally, higher risk reductions were observed for patients with triple negative breast cancers than hormone receptor positive breast cancers (aHR=0.44 for triple negative vs 0.80 for hormone receptor positive).

Risk-reducing mastectomy reduced the risks of disease free survival events (aHR=0.58, 95%CI 0.52–0.65) and breast cancer free interval survival events (aHR=0.55, 95%CI 0.48–0.62).

Risk-reducing salpingo-oophorectomy reduced the risks of disease free survival events (aHR=0.68, 95%CI 0.61–0.77) and breast cancer free interval events (aHR=0.65, 95%CI 0.57–0.74).

Limitations of the study include its retrospective design and the inclusion of patients from different healthcare systems with different resources and guidelines.

While the results of the study may help to improve counselling on cancer risk management strategies for BRCA carriers with young-onset breast cancer, said Lambertini, they should not be used to counsel BRCA-mutation carriers who are healthy, or BRCA-mutation carriers diagnosed with breast cancer at an older age. He also highlighted the critical need for healthcare providers to weigh the risks and benefits of the procedures, as they can lead to infertility and early menopause.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • bilateral mastectomy
  • BRCA gene mutations
  • BRCA1 carriers
  • BRCA2 carriers
  • early-onset breast cancer
  • management
  • risk-reduction
  • salpingo-oophorectomy
  • surgery
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Articles
  • Delivery of Care

Humour: an essential tool in cancer care and communication

  • 18 December 2024
  • Paweł Walewski
View Post
Next Article
  • News

Second-generation BTK inhibitor shows promise as fixed-duration therapy in CLL

  • 18 December 2024
  • Janet Fricker
View Post
You May Also Like
View Post
  • Articles
  • News

CancerWorld issue #103 (May, 2025)

  • Yeva Margaryan
  • 11 May 2025
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Janet Fricker
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Janet Fricker
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Janet Fricker
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • CancerWorld issue #103 (May, 2025)
    • 11 May 2025
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
Article
  • Why Patient-Reported Outcomes are Rarely Used in Trials, and How We Change That
    • 27 May 2025
  • A Promise Kept: How Samvel Danielyan Lifted Pediatric Cancer Survival from Zero to 70%
    • 25 May 2025
  • Together, She Changed Everything: Martine Piccart ’s Fight Against Breast Cancer
    • 20 May 2025
Social

Would you follow us ?

Contents
  • A Promise Kept: How Samvel Danielyan Lifted Pediatric Cancer Survival from Zero to 70%
    • 25 May 2025
  • Together, She Changed Everything: Martine Piccart ’s Fight Against Breast Cancer
    • 20 May 2025
  • Adrian Gottschalk: Making a Difference for His Fellow Human Beings
    • 10 May 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.